Market Research Report: Point-of-Care Molecular Diagnostics Market
Forecast Period: 2026–2036
Market Size (2026): USD 5.8 billion
Projected Market Size (2036): USD 15.1 billion
CAGR (2026–2036): 10.0%

Request full Report Pricing and Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-14279

Global Point-of-Care Molecular Diagnostics Market Forecast Signals New Opportunities for Diagnostic Manufacturers

The global point-of-care molecular diagnostics market is entering a period of significant expansion as healthcare providers increasingly prioritize rapid, accurate, and accessible molecular testing. According to Future Market Insights (FMI), the market is estimated at USD 5.8 billion in 2026 and is projected to reach USD 15.1 billion by 2036, registering a compound annual growth rate (CAGR) of 10.0%.

The projected expansion reflects increasing demand for molecular assays, rapid infectious disease detection, and diagnostic solutions that support clinical decision-making across hospitals, physicians' offices, and outpatient healthcare settings. The market is expected to generate an additional USD 9.3 billion in revenue between 2026 and 2036.

What Is Driving Growth in the Point-of-Care Molecular Diagnostics Market?

Demand is supported by the growing need for rapid testing across respiratory diseases, sexually transmitted diseases, and hospital-acquired infections. Healthcare providers are increasingly adopting molecular diagnostic solutions that enable faster identification of pathogens and support timely treatment decisions.

Regulatory compliance, evolving clinical protocols, hospital modernization, and expanding near-patient testing infrastructure are further supporting market development.

Another important growth driver is the increasing adoption of real-time polymerase chain reaction (RT-PCR) technology. However, reimbursement constraints, institutional pricing pressure, and lengthy regulatory approval timelines remain important challenges for manufacturers.

Assays and Kits and RT-PCR Create Segment Opportunities

FMI identifies Assays and Kits as the leading product segment, accounting for 52.7% of market share in 2026. Demand is supported by respiratory disease assays, influenza testing kits, coronavirus detection kits, and sexually transmitted disease assays.

By technology, Real Time Polymerase Chain Reaction leads with a 64.2% share in 2026. Its position reflects established clinical applications, diagnostic reliability, and demand for rapid molecular testing.

Cancer and oncology assays represent an additional growth opportunity, particularly through genetic mutation detection and tumor marker panels. These applications are expanding the potential use of molecular diagnostics beyond infectious disease testing.

Regional Outlook: Japan and the USA Lead Growth Opportunities

FMI's country-level projections identify Japan and the United States as the fastest-growing markets during the forecast period.

Japan's point-of-care molecular diagnostics market is projected to expand at a 10.3% CAGR, supported by PMDA approval pathways, aging population demographics, and hospital automation investment.

The United States is forecast to grow at a 10.2% CAGR, driven by established FDA regulatory pathways, Medicare reimbursement structures, and high per-capita utilization of assays and kits across hospital and ambulatory settings.

Other markets also present attractive opportunities. The EU is projected to grow at 10.1%, South Korea at 10.0%, and the United Kingdom at 9.8% through 2036.

These markets offer opportunities for diagnostic manufacturers to expand regulatory-approved product portfolios, strengthen institutional partnerships, and improve access to near-patient molecular testing.

Competitive Landscape: Top Players in the Point-of-Care Molecular Diagnostics Market

Competition includes established diagnostic manufacturers with regulatory approval portfolios, clinical evidence, and institutional procurement relationships. FMI identifies the following five key companies:

·         Abbott Laboratories — Molecular diagnostic solutions and established regulatory clearance portfolios.

·         Cepheid (Danaher Corporation) — Cartridge-based molecular diagnostic platforms and infectious disease and oncology testing.

·         bioMérieux SA — Diagnostic testing solutions and molecular assay capabilities.

·         Roche Diagnostics — Molecular diagnostic technologies and clinical testing solutions.

·         QuidelOrtho Corporation — Diagnostic testing products and healthcare laboratory solutions.

Emerging participants, including Visby Medical, Sherlock Biosciences, Mammoth Biosciences, Biomeme, Detect Inc., and Scope Fluidics, are also targeting specialized diagnostic applications.

Strategic Priorities for Businesses Entering the Point-of-Care Molecular Diagnostics Market

Expand assay portfolios: Develop diagnostic kits addressing respiratory diseases, sexually transmitted diseases, and hospital-acquired infections.

Strengthen RT-PCR capabilities: Improve testing performance, workflow efficiency, and product compatibility across clinical settings.

Accelerate regulatory approvals: Align product development and submissions with regional regulatory requirements.

Build institutional partnerships: Strengthen relationships with hospitals, physicians' offices, diagnostic centers, and healthcare procurement organizations.

Improve cost competitiveness: Address pricing pressure and reimbursement constraints through manufacturing efficiencies and optimized product portfolios.

Future Outlook for the Global Point-of-Care Molecular Diagnostics Market

The projected expansion of the point-of-care molecular diagnostics market creates significant opportunities for diagnostic manufacturers, healthcare technology providers, and molecular assay developers. Companies that combine reliable assay performance, regulatory compliance, and cost-effective testing solutions are positioned to strengthen their competitive presence through 2036.

Access the Full Point-of-Care Molecular Diagnostics Market Report

For detailed market forecasts, segmentation, country-level analysis, competitive benchmarking, and strategic opportunities, access the full report from Future Market Insights:

https://www.futuremarketinsights.com/reports/point-of-care-molecular-diagnostics-market

Explore More Research Reports by FMI

Clinical Diagnostics Market - 

https://www.futuremarketinsights.com/reports/clinical-diagnostics-market

At-Home Testing Market -

https://www.futuremarketinsights.com/reports/at-home-testing-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the United States, the United Kingdom, India, and Dubai, FMI provides data-backed insights and strategic intelligence across more than 30 industries and 1,200 markets worldwide.

For Press & Corporate Inquiries

Rahul Singh AVP – Marketing and Growth Strategy

Future Market Insights, Inc.

+91 8600020075

For Sales: sales@futuremarketinsights.com

For Media: Rahul.singh@futuremarketinsights.com

For Web: https://www.futuremarketinsights.com/